Spirair

Treating subjects with implant and delivery device for correction of cartilaginous septal deviation

To qualify for this study, potential study participants must:

• Be 21 years and older

Chronic Rhinosinusitis With Nasal Polyps

The CONTRAST-NP research study is assessingan investigational medicine for Chronic Rhinosinusitis with Nasal Polyps.

To qualify for this study, potential study participants must:

• Be 18 years and older
• Have been diagnosed with Chronic Rhinosinusitis with nasal polyps in both sides of your nose (bilateral)
• Have had treatment in past two years with (or are intolerant of) systemic corticosteroids and/or have had nasal polyp
• surgery
• Have ongoing symptoms such as nasal congestion for at least 8 weeks prior to study screening

Ibuzatrelvir

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With Coronavirus Disease 2019 (COVID-19) Who Are Not Hospitalized But Are at Risk For Severe Disease

• 12 to < 18 years of age, weighing at least 40 kg, or ≥18 years of age of any weight at screening.
• Presence of risk factors for progression to severe COVID-19 at the time of screening based on age:
• 12 to 49 years of age with at least two risk factors, where one must be moderate immunocompromise;
• 50 to 64 years of age with at least two risk factors;
• 65 to 74 years of age with at least one risk factor;
• For participants 75 years of age or older, there are no requirements related to risk factors.

Lebrikizumab

A study to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis with nasal polyps treated with intranasal corticosteroids

• Adult participants ≥18 years of age at time of signing the informed consent form (ICF) and adolescent participants ≥12 to < 18 years of age and weighing ≥ 40 kg at Visit
• Physician-diagnosed CRS with bilateral NP.
• Prior treatment with SCS for CRS or CRSwNP within the last 2 years (or a medical contraindication or intolerance to SCS), prior surgery for NP, or both.
• Endoscopic bilateral NPS score of at least 5 out of 8, with a minimum score of 2 in each nasal cavity performed at screening (Visit 1) and baseline (Visit 3).
• Ongoing symptoms for at least 8 weeks prior to study entry (screening [Visit 1]), including:
• Nasal congestion with moderate or severe symptom severity (score 2 or 3) at screening (Visit 1) (single day for Visit 1) and a weekly average severity score of at least 1 (range 0 to 3) at randomization (average of the 14 days prior to Visit [baseline]), and
• At least one other symptom, such as, but not limited to, partial loss of smell (hyposmia), total loss of smell (anosmia), or anterior or posterior rhinorrhea.
• Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.

Itepekimab

A 52 week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequatelycontrolled chronic rhinosinusitis with nasal polyps

• Participants must be 18 years of age or older, at the time of signing the informed consent.
• Participants with a history of CRSwNP for at least 1 year prior to screening.
• Participants must have at least one of the following features:
• Prior sinonasal surgery for NP.
• Worsening symptoms of CRS requiring treatment with SCS within the prior 2 years before screening (Visit 1).
• Worsening symptoms of CRS in the past 2 years which would have required treatment with SCS, however participant is intolerant or has a contraindication to SCS.
• An endoscopic bilateral NPS of at least 5 out of maximum score of 8 (with a minimum score of 2 in each nasal cavity) at screening and randomization.
• Ongoing symptoms (for at least 12 weeks before Visit 1) of:
• Nasal congestion/blockade/obstruction with moderate or severe (symptom severity score 2 or 3) at Visit 1 and a weekly average severity of greater than 1 in the week before randomization (Visit 2),
AND
• At least one of the following two symptoms: loss of smell or rhinorrhea (anterior/posterior).score of 2 in each nasal cavity) at screening and randomization.

VivAer

Do you suffer from chronic nasal obstruction

• Are 22 years of age or older
• Experience severe nasal airway obstruction
• Plan to undergo the VivAer procedure to help improve your nasal breathing